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Abstract
YAP1 and TAZ (WWTR1) oncoproteins are the ﬁnal transducers of the Hippo tumor suppressor pathway. Deregula-
tion of the pathway leads to YAP1/TAZ activation fostering tumorigenesis in multiple malignant tumor types, includ-
ing sarcoma. However, oncogenic mutations within the core components of the Hippo pathway are uncommon.
Ewing sarcoma (EwS), a pediatric cancer with low mutation rate, is characterized by a canonical fusion involving
the gene EWSR1 and FLI1 as the most common partner. The fusion protein is a potent driver of oncogenesis, but sec-
ondary alterations are scarce, and little is known about other biological factors that determine the risk of relapse or
progression. We have observed YAP1/TAZ expression and transcriptional activity in EwS cell lines. Analyses of 55 pri-
mary human EwS samples revealed that high YAP1/TAZ expression was associated with progression of the disease
and predicted poorer outcome. We did not observe recurrent SNV or copy number gains/losses in Hippo pathway-
related loci. However, differential CpG methylation of the RASSF1 locus (a regulator of the Hippo pathway) was
observed in EwS cell lines compared with mesenchymal stem cells, the putative cell of origin of EwS. Hypermethyla-
tion of RASSF1 correlated with the transcriptional silencing of the tumor suppressor isoform RASFF1A, and tran-
scriptional activation of the pro-tumorigenic isoform RASSF1C, which promotes YAP1/TAZ activation. Knockdown
of YAP1/TAZ decreased proliferation and invasion abilities of EwS cells and revealed that YAP1/TAZ transcription
activity is inversely correlated with the EWS–FLI1 transcriptional signature. This transcriptional antagonism could
be explained partly by EWS–FLI1-mediated transcriptional repression of TAZ. Thus, YAP1/TAZ may override the tran-
scriptional program induced by the fusion protein, contributing to the phenotypic plasticity determined by dynamic
ﬂuctuation of the fusion protein, a recently proposed model for disease dissemination in EwS.
© 2019 The Authors. The Journal of Pathology published by JohnWiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Ewing sarcoma (EwS) represents the second most com-
mon primary malignant bone tumor in children and
young adults [1]. Owing to multimodal treatment con-
cepts, 2/3 of patients with localized disease achieve sus-
tained remission but approximately 30% relapse.
Patients at relapse or with advanced disease have limited
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chance to survive, with a 3-year event-free survival of
less than 25% [2,3]. While clinical prognostic markers
such as the presence of metastases or tumor volume are
established, little is known about the biological factors
determining the risk of progression, thus precluding
risk-adapted therapeutic approaches. EwS was the ﬁrst
solid malignancy deﬁned by the presence of tumor-
speciﬁc EWSR1–ETS gene fusions [4], mainly
EWSR1–FLI1 translocations, which are considered
the main driver of the disease, but fusion type itself
does not have any impact on disease progression [5].
As in most developmental cancers, additional recur-
rent mutations are scarce. The most common somatic
mutations have been detected in STAG2, CDKN2A,
and TP53, associated with poor prognosis [6,7]. Copy
number variation studies by the PROVABES Consor-
tium using samples derived from the EURO-E.W.I.N.
G. 99 (EE99) and EWING 2008 trials showed that
chromosome 1q gain and possibly chromosome 16q
loss deﬁne patients with a poor clinical outcome
(Díaz-Martín et al, unpublished data), supporting pre-
vious retrospective studies [7,8]. However, these sec-
ondary alterations occur with a frequency that does
not account for the large proportion of patients who
relapse.
The Hippo tumor suppressor pathway plays a criti-
cal role in tissue and organ size regulation by restrain-
ing cell proliferation and apoptosis under homeostatic
conditions [9]. Central to the Hippo pathway is a con-
served cascade of adaptor proteins and inhibitory
kinases that regulate the activity of the oncoproteins
YAP1 and TAZ, the ﬁnal effectors of this pathway in
mammals. YAP1/TAZ do not directly bind to DNA,
but act as transcriptional coactivators of target genes
involved in cell proliferation and survival through
their interaction with transcriptional regulators such
as TEAD factors [10]. The role of YAP1 and TAZ as
important drivers in tumorigenesis has been exten-
sively reported in carcinomas, and they also contribute
to malignancies of mesenchymal origin [11–13]. In
fact, given its key function in developmental pro-
cesses, an important role has been inferred for Hippo
signaling in pediatric cancer [14]. Despite this,
somatic or germline mutations in Hippo pathway
genes are uncommon, in comparison to other well-
deﬁned signaling pathways that are commonly dis-
rupted in cancer [13,15]. Since secondary genetic
alterations are scarce in EwS and given the established
role of YAP1 and TAZ in cancer without engaging
mutation, we aimed to explore the contribution of
these factors to oncogenesis in EwS. Herein, we eval-
uated a series of 55 EwS patients by immunohisto-
chemistry (IHC) for expression/activation of YAP1
and TAZ. We observed a signiﬁcant association of
YAP1/TAZ nuclear expression and disease progres-
sion, as well as a potential mechanism of dysregula-
tion involving epigenetic regulation of the RASSF1
locus. Moreover, we demonstrated an interesting
interplay between TAZ/YAP1 function with the
fusion protein, which ﬁts into a recent model concept
for metastatic spreading in EwS based on ﬂuctuations
of the expression of the fusion protein [16].
Materials and methods
Tumor samples, TMA construction, and
immunohistochemistry (IHC)
Tissue samples were obtained from the HUVR-IBiS
Biobank (Universitary Hospital Virgen del Rocio–
Institute of Biomedicine of Seville Biobank, Andalusian
Public Health System Biobank). This study was per-
formed following standard Spanish ethical regulations
and was approved by the corresponding ethics commit-
tee of the Hospital Virgen del Rocío de Sevilla and the
Fundación Pública Andaluza para la Gestión de la Inves-
tigación en Salud de Sevilla (FISEVI), Spain. Written
informed consent was obtained from all patients and all
clinical analyses were conducted in accordance with
the principles of the Declaration of Helsinki.
In this study, we analyzed 88 formalin-ﬁxed, parafﬁn-
embedded (FFPE) samples from 68 different EwS
patients (55 samples corresponding to primary tumor).
We also analyzed a subset of 21 frozen samples from
the same series (17 primary tumors and four metastasis).
Clinical diagnosis of all the samples was performed
according to the World Health Organization (WHO)
classiﬁcation [17], performing ﬂuorescence in situ
hybridization (FISH) to assess the presence of EwS
translocation in tissue sections. The only selection cri-
teria were the availability of pathological data and tissue
for tissue microarray (TMA) construction. Medical
records were retrospectively reviewed and clinicopatho-
logic information for 55 patients with primary tumor
material was retrieved for further analyses (summarized
in Table 1).
Representative tumor areas of EwS samples were
selected on H&E-stained sections and two 1-mm diame-
ter tissue cores were obtained from each specimen to set
up four different TMAs. IHC was carried out on TMA
sections using the Envision method (Dako, CA, USA)
with a step of heat-induced antigen retrieval and using
a primary antibody against YAP1 and TAZ (supplemen-
tary material, Table S1). YAP1/TAZ nuclear staining
was separately evaluated by two pathologists. Tissue
was given a score which resulted from multiplying the
nuclear staining intensity from 0 (no staining) to
3 (strong staining) by the extension based on the percent-
age from positive cells (from 0 to 3). Samples were
grouped as negative or weak positive (score 0–2), and
strong positive (3–9).
Cell culture and transfection
EwS cell lines SKNMC, TTC-466, TC32, A4573, A673,
CADO-ES, RD-ES, RM82, SKES1, STAET10, TC71,
and WE68 were obtained from the EuroBoNet cell line
panel [18]. MDA-MB-231, MCF7, RH30, SA-OS-2,
and PC3 cell lines were purchased from the ATCC
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(Manassas, VA, USA). All tumor cell lines were authen-
ticated by short tandem repeat analyses (CLS, Ger-
many). Primary human bone marrow mesenchymal
cells (hMSCs), immortalized with telomerase reverse
transcriptase, were provided by D Campana [19]. The
A673 cell line engineered to express a doxycycline-
inducible shRNA against EWS–FLI1 was kindly pro-
vided by J Alonso [20]. For the EWS–FLI1 shRNA
induction, 1 μg/ml doxycycline (D9891; Sigma, St
Louis, MO, USA) was added to the media for 48 h.
Detailed information of the immunoﬂuorescence,
siRNA silencing, Crispr KO, luciferase reporter assays,
cell migration, and invasion protocols are described in
supplementary material, Supplementary materials and
methods.
Genome-wide copy number analysis
FFPE samples were sliced into 10-μm-thick sections and
genomic DNA (gDNA)was extracted using the QIAamp
DNA FFPE Tissue Kit (Qiagen, Crawley, UK). DNA
concentration was determined using the Quant-iT™
PicoGreenR dsDNA Assay Kit (Thermo Fisher Scien-
tiﬁc, Waltham, MA, USA). Genome-wide copy number
analysis was performed using the OncoScan FFPE
Assay Kit (Affymetrix, Santa Clara, CA, USA) accord-
ing to the manufacturer’s recommendations. Nexus
Express for OncoScan 3 software (BioDiscovery, Haw-
thorne, CA, USA) was used to estimate copy numbers.
The signiﬁcance testing for aberrant copy number
(STAC) method was conducted to evaluate the signiﬁ-
cance of DNA copy number aberrations across the tumor
series.
Methylation array
Methylation data were generated as described in Puerto-
Camacho et al [21]. Data analyses of GSE118872 were
performed using the Bioconductor lumi package [22].
Transcriptome analysis
SK-N-MC cells were transfected with control or a com-
bination of YAP1/TAZ siRNAs for 72 h. Whole tran-
script expression analysis was conducted in four
biological replicates of each sample. A 100 ng aliquot
of total RNA was ampliﬁed using the GeneChip® WT
PLUS reagent kit (Thermo Fisher Scientiﬁc) following
the manufacturer’s instructions. The ampliﬁed cDNA
was quantiﬁed, fragmented, and labeled in preparation
for hybridization to GeneChip® Human Transcriptome
2.0 Array (Thermo Fisher Scientiﬁc) using 5.5 μg of
single-stranded cDNA product and following protocols
outlined in the user manual. CHP ﬁles were analyzed
by Transcriptome Analysis Console (TAC) 4.0 software
(Thermo Fisher Scientiﬁc), which performs statistical
analysis and provides a list of differentially expressed
genes. Gene set enrichment analysis (GSEA v3.0) was
performed to identify targets of YAP1/TAZ that were
over-represented in previous deﬁned gene sets [23,24].
Statistical analyses
Correlation between immunohistochemical YAP1/TAZ
expression and clinicopathological characteristics was
assessed by chi-squared test for the categorical variables.
The Mann–Whitney test was used for the analysis of dif-
ferences of the continuous variable age. EwS-speciﬁc
survival was deﬁned as the time from surgery to the time
of death from EwS, with deaths from other causes being
censored, whereas in time to relapse analysis, the end
point was EwS recurrence, either local or distant. Sur-
vival curves were estimated using the Kaplan–Meier
method, and the differences in survival were evaluated
using the long-rank test. Cox’s proportional hazards
modeling of parameters potentially related to survival
was conducted to calculate hazard ratios (HRs), in both
univariate and multivariate analyses. All of these statisti-
cal analyses were performed using SPSS v20 (SPSS Inc,
Chicago, IL, USA) and JMP10 software (SAS Institute
Inc, Cary, NC, USA). p < 0.05 was considered statisti-
cally signiﬁcant. Statistical analysis of in vitro functional
assays was performed by using SPSS v20.
Results
YAP1/TAZ are expressed in EwS cell lines and tumor
specimens, and are associated with the presence of
metastasis and poor prognosis
First, we examined YAP1/TAZ expression by western
blotting (WB) in 13 EwS cell lines with different patho-
gnomonic gene fusions (Figure 1A). We observed het-
erogeneous expression of both proteins across the cell
Table 1. Clinical and pathologic ﬁndings according to YAP1/TAZ nuclear expression in primary EwS specimens (n = 55)
YAP1/TAZ expression (IHC)
Characteristics Analyzable Negative/weak positive Strong positive p
Age (years) mean 55 20.72 (2.062) 20.93 (3.196) 0.9088
Location 42 0.4945
Bone 28 (66.67%) 19 (67.86%) 9 (32.14%)
Soft tissue 14 (33.33%) 8 (57.14%) 6 (42.86%)
Progression 50 0.0054
No 27 (54%) 21 (77.78%) 6 (22.22%)
Yes 23 (46%) 9 (39.13%) 14 (60.87%)
p value in bold indicates a signiﬁcant association (p < 0.05) of YAP1/TAZ staining with the corresponding characteristic.
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line panel. Some of the EwS cell lines showed YAP1/
TAZ expression comparable to cell lines in which a rel-
evant role has been described for these factors
(i.e. MDA-MB-231, a triple-negative breast cancer cell
line with NF2 mutations leading to activation of
YAP1/TAZ) [25]. YAP1/TAZ expression was also
detected in human mesenchymal stem cells (hMSCs)
derived from bone marrow, a proposed cell of origin of
EwS. Importantly, nuclear expression was observed by
subcellular fractionation and immunoﬂuorescence
(Figure 1B,C and supplementary material, Figure S1),
suggesting functional transcriptional activity which
was conﬁrmed with luciferase reporter assays
(Figure 1D).
To test whether YAP1/TAZ abundance was associ-
ated with clinical variables in EwS, we analyzed their
expression by IHC in a retrospective series of 55 primary
tumors (Table 1). YAP1/TAZ-strong expressing tumor
cells exhibited intense nuclear staining with a variable
signal in the cytoplasm (Figure 2A). YAP1/TAZ expres-
sion was also observed in endothelial cells in negative
samples, providing an internal positive control for the
IHC determination (Figure 2B). YAP1/TAZ strong
expression was associated with disease progression
(chi-squared test, p < 0.0054), whereas no signiﬁcant
association was observed with age at surgery or location
(Table 1). We also observed increased YAP1/TAZ pos-
itivity in metastatic or relapsed tumors in 11 patients
with paired primary tumor samples (Figure 2C–I, paired
t-test, p = 0.0204). Additional non-paired metastatic or
relapsed tumor samples showed preferential strong
expression as well (Figure 2J, Fisher’s exact test,
p = 0.006).
We retrieved follow-up data for the EwS patients with
primary tumor biopsies to evaluate prognosis (median
duration of follow-up 35.23 months), but only 45 had a
known relapse date (median duration of follow-up
41.43 months). YAP1/TAZ expression inﬂuenced sig-
niﬁcantly the time to relapse, which was shorter in strong
positive patients than in weak/negative patients (mean
127.4 versus 50.66 months, p = 0.011, Figure 2K). Sim-
ilarly, Kaplan–Meier estimates of EwS-speciﬁc survival
were shorter (but not signiﬁcantly) for the YAP1/TAZ
strong positive group compared with the YAP1/TAZ
weak/negative group (mean 129.32 versus 73.61months,
p = 0.159, Figure 2L). Accordingly, Cox regression
Figure 1. YAP1 and TAZ are expressed and active in EwS cell lines. (A) Western blot using a monoclonal antibody recognizing total levels of
YAP1 and TAZ proteins in a panel of 13 EwS cell lines. Basal and luminal breast cancer (MDA-MB-231, MCF-7), prostate cancer (PC3), oste-
osarcoma (SA-OS-2), rhabdomyosarcoma (RH30), and human mesenchymal stem cells (hMSC) were included in the assay. (B) Nucleus and
cytoplasm subcellular lysates were assessed by WB (T, total extract; N, nucleus; C, cytoplasm). (C) Immunoﬂuorescence images using the indi-
cated antibodies (60× original objective magniﬁcation). (D) YAP1/TAZ-TEAD-dependent transcriptional activity in EwS cell lines was evalu-
ated with luciferase reporter constructs containing sequences with or without TEAD elements (8×TEAD and TnT-minP constructs,
respectively). A Crispr-edited cell line was assessed as an additional negative control (SK-N-MC YAP KO). RLU (relative luminescence units)
was normalized to Renilla luciferase values. Data are shown as mean  SEM of three biological replicates (*p < 0.001).
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Figure 2. YAP1/TAZ expression is associated with disease progression. (A) Representative image for YAP1/TAZ strong positive expression in a
primary EwS tumor (40× original objective magniﬁcation). (B) Staining of endothelial cells can be observed in a negative tumor specimen.
(C–H) Immunostaining for YAP1/TAZ in primary tumors (left) and matched metastasis (right) of the same patients (40×). (I) Comparison of
YAP1/TAZ immunostaining in 11 matched biopsies (p = 0.024, paired t-test). (J) Distribution of samples in each tumor category (primary ver-
sus metastasis or relapse) according to YAP1/TAZ staining score. The number of samples is indicated on the bars (p = 0.006, Fisher’s exact
test). (K, L) Kaplan–Meier survival curves for YAP1/TAZ protein expression in EwS patients grouped as negative/weak positive versus strong
positive staining.
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univariate analyses determined that YAP1/TAZ strong
expression was signiﬁcantly correlated with the time to
relapse but not with EwS-speciﬁc survival, with the
unadjusted hazard ratio (HR) being 3.354 (p = 0.016)
and 1.928 (p = 0.167), respectively (Table 2). A signiﬁ-
cant correlation with survival and time to relapse was
also observed for metastasis (Table 2). These variables
were all included simultaneously, to assess the indepen-
dent prognostic signiﬁcance based on multivariate anal-
ysis. The adjusted HR of YAP1/TAZ strong expression
for relapse did not reach signiﬁcant conﬁdence after con-
trolling the Cox’s regression model for the effects of age,
tumor location, and metastasis. However, a signiﬁcant
HR for YAP1/TAZ was obtained in the multivariate
analysis regarding overall survival (Table 2).
Activation of YAP1/TAZ in Ewing sarcoma
We tried to determine the mechanisms that contribute to
YAP1/TAZ activation in EwS. We did not ﬁnd any
recurrent somatic mutation in Hippo pathway-related
genes in public datasets (supplementary material,
Figure S2). Next, we analyzed copy number alterations
in a series of 24 EwS using SNP arrays (Figure 3). Gross
chromosomal alterations were similar to previous
reports, i.e. gains of whole chromosomes 8 and 12 [7].
Copy number gain in the WWTR1 locus, with complete
gain of chromosome 3, was detected in a single case.
Gain at the YAP1 locus was detected in another case with
an almost tetraploid genotype. Regarding the core regu-
latory kinases of the Hippo pathway and other negative
regulators of YAP1/TAZ, no signiﬁcant copy-loss
events were observed (Figure 3). Focal copy number
aberration events in Hippo-related loci were also pre-
cluded after inspecting the data with the STAC algo-
rithm (supplementary material, Table S2). Similarly,
Hippo-related loci were unaffected in a retrospective
series of 165 cases of EwS, which was analyzed within
the PROVABES Consortium for validation of bio-
markers in EwS (https://www.medizin.uni-muenster.
de/provabes/network, Díaz-Martín J, unpublished data).
Deregulation of the Hippo pathway leading to YAP1/
TAZ activation could be the consequence of epigenetic
silencing of tumor suppressor genes through DNA
hypermethylation [11,15,26]. We inspected previous
results of the group comparing CpG methylation in
EwS cell lines versus hMSCs from EwS patients and
healthy donors (GSE118872) [21].RASSF1was the only
Hippo-related locus showing differential methylation
(Figure 4A). Hypermethylation of RASSF1 accounts
for the silencing of RASSF1A transcript expression, but
promotes switching to an alternative gene promoter driv-
ing the expression of the isoform RASSF1C. RASSF1A
contributes to Hippo pathway-mediated repression of
YAP1/TAZ, whereas RASSF1C promotes Src family
kinase (SFK)-mediated activation of YAP1 [27]. We
conﬁrmed the expression of the alternative isoform
RASSF1C in EwS cell lines, whereas RASSF1A
Figure 3. Summary of the copy number aberrations detected in 24 EwS samples. Frequencies of copy number gain (above axis, blue) and copy
number loss (below axis, red) across the human genome. Hippo-related loci are indicated: Tumor suppressor genes such as core kinases of the
pathway are marked in black, and oncogenes WWTR1 and YAP1 in red.
Table 2. Prognostic value of YAP1/TAZ IHC expression in relation to other clinical variables
Time to relapse EwS-speciﬁc survival
Factors Unadjusted
HR (95% CI)
p Adjusted
HR (95% CI)
p Unadjusted
HR (95% CI)
p Adjusted HR
(95% CI)
p
TAZ/YAP1 (strong versus
negative/weak)
3.354
(1.253–8.974)
0.016 1.579
(0.287–8.676)
0.599 1.928
(0.761–4.886)
0.167 5.703
(1.004–32.400)
0.049
Metastasis 14.895
(4.675–47.455)
<0.001 70.369
(4.980–994.326)
0.002 11.318
(3.211–39.895)
<0.001 77.954
(7.332–828.754)
<0.001
Age 0.967
(0.916–1.022)
0.234 1.034
(0.924–.1022)
0.557 0.970
(0.925–1.017)
0.208 0.971
(0.888–1.062)
0.523
Location (bone versus
soft tissue)
2.491
(0.667–9.294)
0.174 2.612
(0.468–14.594)
0.274 1.066
(0.326–3.483)
0.916 2.640
(0.478–14.570)
0.265
HR, hazard ratio; CI, conﬁdence interval. p numbers in bold highlight signiﬁcant HR (p < 0.05).
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expression was absent or reduced (with the exception of
the STAET-10 and TC-32 cell lines) compared with
hMSCs (Figure 4B). Moreover, expression of YAP1/
TAZ target genes positively correlated with RASSF1C
expression in the cell line panel, as well as in EwS tumor
specimens (Figure 4B,C). Interestingly, TAZ, but not
YAP1, seems to be transcriptionally regulated as CTGF
expression correlated with TAZ mRNA expression
(Figure 4C). Correlation of TAZ mRNA levels with
Hippo target genes was also observed in larger EwS series
in public repository expression data (supplementary
material, Figure S3).
There is extensive evidence that SFKs can directly
phosphorylate YAP1 and TAZ, promoting their activity
and stability [28]. Therefore, since RASSF1C acti-
vates SFKs in RASSF1-methylated cells [27], we
blocked SFK activity by exposing EwS cells to
dasatinib. Inhibition of SFKs, monitored as SRC
phosphorylation, resulted in reduced cell viability
(SK-N-MC IC50 = 6.55 μM; TTC-466 IC50 = 2.11 μM)
and downregulation of YAP1/TAZ target genes
(Figure 5A). Upon dasatinib treatment, the mRNA levels
of YAP1 and TAZ remained unaffected, but TAZ
protein expression was decreased and YAP1 inactivat-
ing phosphorylation S127 increased in both cell lines
(Figure 5A). As an alternative approach of pharmaco-
logic blockade of YAP1/TAZ activity, we tested pitavas-
tatin. Statins prevent nuclear localization of YAP1/TAZ
via inhibition of the enzyme HMG-CoA reductase, ulti-
mately affecting the metabolic control of YAP1/TAZ by
the mevalonate pathway [29]. We also observed an anti-
proliferative effect upon pitavastatin treatment (SK-N-
MC IC50 = 1.83 μM; TTC-466 IC50 = 1.86 μM), with
mild reduction of YAP1/TAZ target genes and TAZ pro-
tein downregulation (Figure 5A). Neither dasatinib nor
pitavastatin treatments affected EWS–FLI1 expression
in the SK-N-MC cell line, thus precluding that the anti-
proliferative effect of these drugs was mediated by the
fusion protein.
YAP1/TAZ loss-of-function affects cell proliferation
and invasion capacity in EwS cells
To assess the oncogenic properties of YAP1 and TAZ
in EwS cells, we induced transient knockdown of
YAP1, TAZ or simultaneous depletion of both factors
(supplementary material, Figure S4), and evaluated cell
proliferation, invasion, and migration capacity of the
silenced cells. We observed inhibition of proliferation
for every individual or combined siRNA transfection.
Individual depletion of YAP1 inhibited cell growth
more efﬁciently than TAZ silencing (supplementary
material, Figure 5B). Accordingly, Crispr-mediated
knockout (KO) of YAP1 reduced colony formation
in vitro and impaired tumor growth in a subcutaneous
xenograft model (Figure 5D,E).
YAP1/TAZ silenced cells showed a signiﬁcantly
reduced invasive capacity as well (Figure 5C). The
migration capacity of EwS cells upon YAP1/TAZ
silencing was not signiﬁcantly altered compared with
the control, but a slight trend toward diminished migra-
tion was observed in the double-silenced cells (supple-
mentary material, Figure S5).
YAP1/TAZ-driven transcription activity is inversely
correlated with the EWS–FLI1 transcriptional
signature
To evaluate the transcriptome modulation by YAP1/
TAZ, we conducted gene expression proﬁling using
Affymetrix microarrays in SK-N-MC cells upon simulta-
neous silencing of both factors. The microarray data have
been deposited in the NCBI Gene Expression Omnibus
(accession code GSE120512; https://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE120512). We observed
differential expression of 938 coding genes (supplemen-
tary material, Table S3) including well-established
YAP1/TAZ target genes, such as CYR61, CTGF,
and AMOTL2, which were conﬁrmed by RT-qPCR ana-
lyses in two EwS cell lines with different gene
fusions (Figure 6A). Similar results were obtained with
individual silencing of each factor (supplementary mate-
rial, Figure S6). Of note, the expression levels of EWS–
FLI1 were not affected in SK-N-MC (Figure 6A) or
other EwS cell lines tested (supplementary material,
Figure S6).
Next, we collated this transcriptional proﬁle with
previously published curated gene sets. Interestingly,
we found signiﬁcant enrichment for several EwS-
related gene signatures both in YAP1/TAZ-correlated
and in YAP1/TAZ-inversely correlated genes (Table 3
and Figure 6B). YAP1/TAZ-inversely correlated genes
were signiﬁcantly over-represented among EwS
induced gene sets, and YAP1/TAZ-correlated genes
overlapped with EwS repressed genes, thus suggesting
opposite transcriptional activity of EWS–FLI1 chime-
ric protein and YAP1/TAZ factors. Accordingly, deple-
tion of the EWS–FLI1 protein in the A673 EwS cell line
resulted in the induction of YAP1/TAZ-regulated
genes, as well as the TAZ but not the YAP1 factor,
the latter showing a slight increase in the phosphory-
lated fraction (Figure 6C, left and center panels). TAZ
protein upregulation upon EWS–FLI1 silencing could
be observed in both nuclear and cytoplasmic compart-
ments (Figure 6C, right panel). Therefore, transcrip-
tional antagonism may be explained partially by EWS–
FLI1-mediated downregulation of TAZ. We conﬁrmed
these observations in public datasets for EWS–FLI1
silencing in ﬁve EwS cell lines [30], and for ectopic
expression of EWS–FLI1 in embryonic stem cells [31]
(supplementary material, Figure S7). These observations
are in accordance with recent reports describing that sev-
eral genes are inversely regulated by TEAD factors and
EWS–FLI1 [32,33]. TEADs are the main transcription
factor partners of YAP1 and TAZ, and usually associate
with AP-1 transcription factors at distal enhancers
[25,34]. Both TEAD and AP-1 conserved binding
motifs are present in EWS–FLI1 regulated genes [32].
Furthermore, EWS–FLI1 binding at the WWTR1
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locus coding for TAZ correlates with a decrease of TAZ
mRNA expression, suggesting direct repression of TAZ
by EWS–FLI1 (supplementary material, Figure S8).
Discussion
In the present study, we have shown that YAP1/TAZ
nuclear expression is associated with disease progres-
sion and poor prognosis in a large retrospective series
of EwS patients. Few reports have addressed this issue
so far, and the reported series were smaller, i.e. Ahmed
et al [35] observed that YAP1 expression can be
detected in 47% of samples (in a series of 32 cases) with-
out an association with survival, whereas in another
study with only ﬁve EwS cases, 60% and 80% showed
YAP1 and TAZ expression, respectively [36]. Other
pediatric sarcomas such as rhabdomyosarcoma, osteo-
sarcoma, and neuroblastoma have been reported to
express YAP1 and TAZ, with an impact on patient prog-
nosis and conferring resistance to current therapies
[37–41]. Moreover, recent studies have revealed that
YAP1/TAZ are key signaling mediators of the onco-
genic fusion genes in synovial sarcoma, myxoid liposar-
coma, and alveolar rhabdomyosarcoma [42–44]. This
positive functional cooperation in translocated sarcomas
contrasts with the antagonism between YAP1/TAZ and
EWS–FLI1 that we have observed in EwS.
Another fact that supports the relevance of YAP1/TAZ
and other Hippo signaling effectors in sarcomas is their
involvement in recurrent fusion genes in certain histolog-
ical types [45,46]. Notwithstanding, aberrant activation of
YAP1/TAZ in cancer is often promoted by mechanisms
not involving somatic alterations. We have observed that
epigenetic regulation of theRASSF1 locus could affect the
expression of YAP1/TAZ target genes in EwS cell lines
(Figure 4). This result may explain previous observations
describing a correlation of hypermethylation of RASSF1
Figure 4. DNA methylation proﬁling of EwS cell lines and MSCs revealed differential CpG methylation in the RASSF1 locus. (A) Heat map
depicting CpG methylation levels of Hippo-related loci across a panel of EwS cell lines and hMSCs from EwS patients and healthy donors.
(B) Relative quantiﬁcation by RT-qPCR of RASS1A and RASSF1C transcripts and TAZ/YAP1 target genes in a panel of EwS cell lines. A basal
breast cancer cell line and hMSCs were included as controls (experiments were performed with three biological samples in triplicates).
(C) Correlation analyses of mRNA expression levels (RT-qPCR) of CTGF with RASSF1C, RASSF1A, TAZ, and YAP1 from a series of 21 frozen
EwS tumor specimens (r, Pearson’s correlation coefﬁcient).
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and RASSF2with worse clinical outcome in EwS [47,48].
Moreover, Src kinase activation of invadopodia in
response to stress in EwS [49] could be related to SFK-
mediated activation of YAP1/TAZ by RASSF1C
(Figure 5A). However, YAP1/TAZ activation does not
seem to rely on RASSF1 hypermethylation in hMSC
(Figure 4), the putative cell of origin of EwS, which
exhibits high expression levels of YAP1 and TAZ
(Figure 1). Unaffected expression of total levels of
YAP1 and derepression of TAZ upon EWS–FLI1
silencing (Figure 6E) also support the notion that both
factors are maybe expressed in the cell of origin, as pro-
posed for ZEB2, an EMT (epithelial–mesenchymal
transition) inducer like YAP1 and TAZ [50].
The association of YAP1/TAZ with metastatic
spread could arguably be related to the relative levels
of the fusion protein, recently reported to promote
phenotypic plasticity of EwS cells [16]. In this sce-
nario, YAP1/TAZ may promote a mesenchymal phe-
notype in EWS–FLI1-depleted EwS cells together
with Wnt/beta-catenin [51], since it is well established
that the crosstalk between Hippo and Wnt signaling is
essential for tumor progression in several types of can-
cer [52]. As has been described for Wnt/beta-catenin
[51], the opposing transcriptional signature between
YAP1/TAZ and EWS–FLI1 could partly contribute
to the metastatic process; i.e. we found strong downre-
gulation or upregulation of LOX (a mediator of metas-
tasis [16]) in YAP1/TAZ-silenced or EWS–
FLI1-silenced cells, respectively. These results sug-
gest that LOX expression in EwS could be explained
by derepression in a low-level state of the fusion pro-
tein and/or inducer mechanisms involving YAP1 or
TAZ. However, we did not observe differences in
LOX expression by IHC in metastatic tumors of eight
matched samples, neither did we ﬁnd differences in
FLI1 or NKX2.2 (EWS–FLI induced target) staining
in the same matched samples (supplementary
Figure S8). Nevertheless, a larger series of paired sam-
ples would be necessary to reach a deﬁnite conclusion.
Figure 5. Pharmacologic inhibition and siRNA silencing of YAP1/TAZ in EwS cells. (A) SK-N-MC and TTC-466 cell lines were treated with vehi-
cle (−, DMSO < 1:1000 v/v), dasatinib (D, 1 μM) or pitavastatin (P, 1 μM) during 24 h, and mRNA levels of YAP1, TAZ, and their target genes
CTGF and CYR61 were quantiﬁed by RT-qPCR. mRNA levels of EWS–FLI1 were evaluated in the SK-N-MC cell line. Whole cell extracts were
also analyzed by WB (experiments were performed with three biological samples in triplicates; *p < 0.05, t-test). (B) Proliferation curves of
EwS cell lines transfected with control siRNA (C), siRNA targeting YAP1 (siY), TAZ (siT) or a combination of siRNAs to deplete both factors
simultaneously (siYT). Two different siRNAs were used to knock down each factor, rendering similar levels of silencing (supplementary mate-
rial, Figure S4). Data are shown for only one of the siRNAs. Results are shown as mean  SD of three independent experiments performed in
triplicate. All the conditions were signiﬁcantly different form the control at day 6 (p < 0.05, t-test). (C) Invasion assay of EwS cell lines upon
individual or combined silencing of YAP1 and TAZ (*p < 0.05, **p < 0.005; t-test). (D) Colony formation assay of the SK-N-MC cell line
(WT, wild type; NT, non-targeting sgRNA; YAP1 KO, CRISPR-mediated KO of YAP1). (E) Time course of tumor growth in mice with the indicated
xenografts.
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ChIP-seq data from Bilke et al [53] reveal that
EWSR1–FLI1 binds at regulatory elements of some of
the well-established TAZ/YAP1 target genes [33]. Fur-
thermore, an inverse correlation between AP-1-induced
genes and the EWSR1–FLI1 transcriptional signature
was observed in the same cell model that we used in this
work: inducible silencing of EWSR1–FLI1 in the A673
cell line [33]. It is well established that YAP1/TAZ/
TEAD transcriptional complexes usually cooperate with
AP-1 at regulatory DNAmodules to synergistically acti-
vate target genes [25,34]. Therefore, the transcriptional
antagonism might be a consequence of some
interference between YAP1/TAZ/TEAD–AP1 com-
plexes and the fusion protein, as demonstrated by
Katschnig et al [32]. Another mechanism contributing
to the opposing gene signatures might involve Ewing
sarcoma-associated transcript 1 (EWSAT1), which we
found to be signiﬁcantly induced in YAP1/TAZ-
silenced SK-N-MC cells (supplementary material,
Table S3). EWSAT1 is a long noncoding RNA that medi-
ates EWS–FLI1 gene repression via interaction with a
heterogeneous nuclear ribonucleoprotein [54]. In addi-
tion, we have observed inhibition of TAZ expression
associated with the presence of EWS–FLI1, which also
Figure 6. YAP1/TAZ induce an EWS–FLI1-opposite gene signature. (A) RT-qPCR assays for YAP1/TAZ target genes in EwS cell lines with different
gene fusions upon siRNA depletion of YAP1 and TAZ (see supplementary material, Figure S6 for RT-qPCRwith individual silencing of each factor).
Experiments were performed with three biological samples in triplicates. (B) Examples of YAP1/TAZ rank-ordered target genes compared with
downregulated and upregulated EWS–FLI1 gene sets, respectively (NES, normalized enrichment score). (C) RT-qPCR (left) and WB assays (center,
right) showing derepression of TAZ and YAP1/TAZ target genes upon silencing of EWS–FLI1 in the cell line A673 (dox, doxycycline induction of
shRNA targeting EWS–FLI1; C, cytoplasm; N, nucleus). Assays were performed with three biological samples in triplicates.
Table 3. EwS gene sets with a positive and negative enrichment score for YAP1/TAZ regulated genes in the SK-N-MC cell line
Gene set NES NOM P value FDR q value
KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN 1.9 < 0.0001 0.053
ZHANG_TARGETS_OF_EWSR1_FLI1_FUSION −2.24 < 0.0001 < 0.0001
RIGGI_EWING_SARCOMA_PROGENITOR_UP −1.97 < 0.0001 0.008
MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_UP −1.84 < 0.0001 0.024
FERREIRA_EWINGS_SARCOMA_UNST_VS_STABLE_UP −1.73 < 0.0001 0.057
NES, normalized enrichment score.
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binds DNA at the WWTR1 locus (supplementary
material, Figure S9). Indeed, regulation of TAZ
seems to occur at the transcriptional level, whereas
YAP1 activity is not correlated with mRNA levels
(Figures 4C and 6E).
In summary, our study reveals that the interplay
between the Hippo pathway effectors YAP1/TAZ and
the function of the gene fusion is relevant to shape
the transcriptional program in EwS. The transcrip-
tional output elicited by these factors deserves further
characterization as our observations provide clinical
evidence that YAP1/TAZ expression is associated
with disease progression in EwS patients. Studies with
larger prospective series are needed in order to corrob-
orate our observations and to establish whether YAP1/
TAZ could serve as reliable biomarkers to stratify and
identify patients who could beneﬁt from targeted
therapies.
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